The growing popularity of GLP-1 receptor agonists like semaglutide and liraglutide among reproductive-age women has created an urgent knowledge gap about pregnancy safety when these medications are stopped before conception. While manufacturers recommend discontinuing these drugs before attempting pregnancy, real-world data on maternal and fetal outcomes remains limited. New research examining pregnancy outcomes after GLP-1RA discontinuation reveals complex patterns in gestational weight gain and birth outcomes that challenge simple safety assumptions. The analysis identified concerning variations in maternal weight trajectories and potential impacts on fetal development, though the clinical significance remains unclear. Women who had used GLP-1 receptor agonists showed altered patterns of gestational weight gain compared to controls, with some experiencing excessive weight gain rebounds while others maintained below-normal weight trajectories throughout pregnancy. However, methodological limitations in the current evidence base prevent definitive safety conclusions. The observational nature of available studies introduces selection bias, as women using these medications may have underlying metabolic conditions that independently affect pregnancy outcomes. Additionally, the timing and duration of pre-conception discontinuation varies significantly across cases, making it difficult to isolate drug effects from baseline health status. For clinicians managing reproductive-age women on GLP-1 therapies, these findings underscore the need for individualized pre-conception counseling and careful monitoring throughout pregnancy. The metabolic benefits of these medications must be weighed against potential reproductive risks, particularly given the lack of randomized controlled data. Until more robust safety data emerges, a cautious approach with enhanced surveillance appears warranted for this vulnerable population.